In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Lucid Diagnostics Inc’s stock clocked out at $1.33, up 2.31% from its previous closing price of $1.30. In other words, the price has increased by $2.31 from its previous closing price. On the day, 1.24 million shares were traded.
Ratios:
To gain a deeper understanding of LUCD’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.72 and its Current Ratio is at 0.75.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Ascendiant Capital Markets on December 27, 2021, initiated with a Buy rating and assigned the stock a target price of $16.
On November 08, 2021, Needham started tracking the stock assigning a Buy rating and target price of $17.
On November 08, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $21.Cantor Fitzgerald initiated its Overweight rating on November 08, 2021, with a $21 target price.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 34.51.
Stock Price History:
Over the past 52 weeks, LUCD has reached a high of $1.80, while it has fallen to a 52-week low of $0.68. The 50-Day Moving Average of the stock is -0.96%, while the 200-Day Moving Average is calculated to be 28.26%.
Shares Statistics:
A total of 84.37M shares are outstanding, with a floating share count of 41.07M. Insiders hold about 62.03% of the company’s shares, while institutions hold 9.78% stake in the company.
Earnings Estimates
A detailed examination of Lucid Diagnostics Inc (LUCD) is currently in progress, with 2.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.09 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.43 and -$0.46 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.3, with 3.0 analysts recommending between -$0.25 and -$0.36.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $1.23M. It ranges from a high estimate of $1.45M to a low estimate of $1M. As of the current estimate, Lucid Diagnostics Inc’s year-ago sales were $976kFor the next quarter, 6 analysts are estimating revenue of $1.86M. There is a high estimate of $2.6M for the next quarter, whereas the lowest estimate is $1.2M.
A total of 6 analysts have provided revenue estimates for LUCD’s current fiscal year. The highest revenue estimate was $8.8M, while the lowest revenue estimate was $4.5M, resulting in an average revenue estimate of $6.71M. In the same quarter a year ago, actual revenue was $4.35MBased on 6 analysts’ estimates, the company’s revenue will be $19.02M in the next fiscal year. The high estimate is $37M and the low estimate is $10M.
